HC Wainwright Issues Optimistic Outlook for DNTH Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Investment analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Dianthus Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($1.03) per share for the quarter, up from their prior forecast of ($1.21). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($4.07) EPS and FY2026 earnings at ($4.60) EPS.

Other equities research analysts also recently issued reports about the company. Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Guggenheim reiterated a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, TD Cowen assumed coverage on Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating on the stock. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of “Buy” and an average price target of $52.14.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $21.33 on Monday. The business’s 50 day moving average price is $22.54 and its 200-day moving average price is $24.81. Dianthus Therapeutics has a fifty-two week low of $18.13 and a fifty-two week high of $33.77. The company has a market cap of $631.30 million, a price-to-earnings ratio of -8.53 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC boosted its position in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. R Squared Ltd bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $26,000. KLP Kapitalforvaltning AS bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $33,000. KBC Group NV bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $35,000. Finally, BNP Paribas Financial Markets bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $59,000. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.